GoAI
Get started
Cronos Group Inc. logo

Cronos Group Inc.

CRON

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Regular session

$3.3254

+$0.0154 · +0.47%

Aug 24, 10:40 AM ETData delayed

CRON company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

56

Fair Value

Momentum

41

Neutral

Sentiment

58

Mixed

Risk resilience

59

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Cronos Group Inc. is a company primarily focused on cannabinoids. In the United States, it develops, promotes, and supplies hemp-derived wellness and beauty products under the Lord Jones and Happy Dance brands, reaching consumers through online sales, traditional retail outlets, and partnerships within the hospitality sector. Beyond hemp, the company also engages in the cultivation, production, and commercialization of cannabis and its related extracts for both therapeutic and recreational consumption. Its cannabis offerings encompass dried flower, pre-rolled joints, edibles, concentrates, and various extracts, which are distributed via wholesale channels and directly to clients. The wellness segment operates under the PEACE NATURALS platform, while its adult-use products are marketed through the Spinach brand. Additionally, Cronos exports dried cannabis and cannabis oils to international markets such as Germany, Israel, and Australia. Founded in 2012, the company's headquarters are located in Toronto, Canada.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
CA
CEO
Michael Ryan Gorenstein
Listed since
Feb 27, 2018
Employees
610

Market position

Day range

Current $3.3254

52-week range

Current $3.3254

Open
$3.31
Previous close
$3.31
Volume
287.28K
0.2× average
Average volume
1.45M
Average daily volume
Market cap
1.24B USD
Beta
1.24
Market reference 1
50-day average
$2.8606
+16.25% above average
200-day average
$2.6884
+23.69% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
223.07M USD
P/E (TTM)
17.71×
P/B (TTM)
1.16×
P/S (TTM)
6.94×
EV / EBITDA
-66.41×
Earnings yield
-0.95%
Free cash flow yield
0.01%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
45.37%
Operating margin
0.30%
Net margin
38.95%
Return on equity
-0.88%
Return on assets
-0.80%
Return on invested capital
-0.27%

Financial health

Debt / equity
0×
Current ratio
19.59×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends107%-155%-417%-679%Gross margin, FY2021: -27.25%Gross margin, FY2022: 17.79%Gross margin, FY2023: 13.65%Gross margin, FY2024: 21.42%Gross margin, FY2025: 41.37%Operating margin, FY2021: -452.24%Operating margin, FY2022: -128.45%Operating margin, FY2023: -97.20%Operating margin, FY2024: -65.07%Operating margin, FY2025: -11.96%Net margin, FY2021: -613.54%Net margin, FY2022: -194.51%Net margin, FY2023: -84.78%Net margin, FY2024: 34.93%Net margin, FY2025: -6.44%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -27.25%. Gross margin FY2022 17.79%. Gross margin FY2023 13.65%. Gross margin FY2024 21.42%. Gross margin FY2025 41.37%. Operating margin FY2021 -452.24%. Operating margin FY2022 -128.45%. Operating margin FY2023 -97.20%. Operating margin FY2024 -65.07%. Operating margin FY2025 -11.96%. Net margin FY2021 -613.54%. Net margin FY2022 -194.51%. Net margin FY2023 -84.78%. Net margin FY2024 34.93%. Net margin FY2025 -6.44%.

Income trends

Revenue

149.15M USD+26.81%

Operating income

−17.84M USD+76.69%

Net income

−9.61M USD−50.69M USD
Income trends across reported periods203.68M USD−14.42M USD−232.53M USD−450.63M USDRevenue, FY2021: 64.56M USDRevenue, FY2022: 86.75M USDRevenue, FY2023: 87.24M USDRevenue, FY2024: 117.62M USDRevenue, FY2025: 149.15M USDOperating income, FY2021: −291.97M USDOperating income, FY2022: −111.43M USDOperating income, FY2023: −84.8M USDOperating income, FY2024: −76.53M USDOperating income, FY2025: −17.84M USDNet income, FY2021: −396.11M USDNet income, FY2022: −168.73M USDNet income, FY2023: −73.96M USDNet income, FY2024: 41.08M USDNet income, FY2025: −9.61M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 64.56M USD. Revenue FY2022 86.75M USD. Revenue FY2023 87.24M USD. Revenue FY2024 117.62M USD. Revenue FY2025 149.15M USD. Operating income FY2021 −291.97M USD. Operating income FY2022 −111.43M USD. Operating income FY2023 −84.8M USD. Operating income FY2024 −76.53M USD. Operating income FY2025 −17.84M USD. Net income FY2021 −396.11M USD. Net income FY2022 −168.73M USD. Net income FY2023 −73.96M USD. Net income FY2024 41.08M USD. Net income FY2025 −9.61M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue149.15M USD117.62M USD87.24M USD86.75M USD64.56M USD
Cost of goods sold87.45M USD92.42M USD75.33M USD71.31M USD82.15M USD
Gross profit61.7M USD25.2M USD11.91M USD15.44M USD−17.59M USD
Research and development4.45M USD4.23M USD5.84M USD13.13M USD21.84M USD
Selling, general, and administrative63.76M USD76.82M USD80.93M USD100.73M USD121.68M USD
Operating expenses79.54M USD101.73M USD96.71M USD126.86M USD274.38M USD
Interest income40.66M USD52.02M USD51.24M USD22.51M USD9.07M USD
Interest expense———13K USD27K USD
Depreciation and amortization14.48M USD9.34M USD8.11M USD13.12M USD15.4M USD
Operating income−17.84M USD−76.53M USD−84.8M USD−111.43M USD−291.97M USD
Net income−9.61M USD41.08M USD−73.96M USD−168.73M USD−396.11M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
36%
4 beats, 5 misses, 2 met estimates
Average EPS surprise
+72.91%
11 comparable reports
Latest EPS result
0.09
Estimate 0.01 · Beat by 800.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.150.05-0.04-0.14Q1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26MissQ2 '26MetQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 0.11, estimate -0.01, surprise +1200.00%, Beat. Q2 2025, reported May 8, 2025: actual 0.02, estimate 0.01, surprise +99.60%, Beat. Q3 2025, reported Aug 7, 2025: actual -0.1, estimate -0.02, surprise -400.00%, Miss. Q4 2025, reported Nov 6, 2025: actual 0.07, estimate 0.02, surprise +250.00%, Beat. Q1 2026, reported Feb 26, 2026: actual -0.005, estimate 0.01, surprise -147.00%, Miss. Q2 2026, reported May 11, 2026: actual 0.01, estimate 0.01, surprise 0.00%, Met estimate. Q3 2026, reported Aug 6, 2026: actual 0.09, estimate 0.01, surprise +800.00%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 0.03, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates55.13M46.22M37.31M28.41MQ1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 30.53M USD, estimate 34.91M USD, surprise -12.55%, Miss. Q2 2025, reported May 8, 2025: actual 33.62M USD, estimate 31.72M USD, surprise +6.00%, Beat. Q3 2025, reported Aug 7, 2025: actual 33.46M USD, estimate 32.9M USD, surprise +1.69%, Beat. Q4 2025, reported Nov 6, 2025: actual 36.34M USD, estimate 37.3M USD, surprise -2.58%, Miss. Q1 2026, reported Feb 26, 2026: actual 44.53M USD, estimate 38.72M USD, surprise +15.01%, Beat. Q2 2026, reported May 11, 2026: actual 45.21M USD, estimate 42.2M USD, surprise +7.13%, Beat. Q3 2026, reported Aug 6, 2026: actual 53.01M USD, estimate 44.2M USD, surprise +19.93%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 49.47M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

2 institutions
CIBCmaintainOutperform

CRON peers

Amgen Inc. logo

AMGN

Amgen Inc.

$440.72

+0.32%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$145.71

-0.28%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$547.55

-0.09%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$379.11

+0.08%

Sanofi logo

SNY

Sanofi

$45.6206

-0.50%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$825.22

-1.06%

ETFs holding CRON

Funds reporting this stock among their holdings, ordered by reported position size.

Amplify Alternative Harvest ETF logoAmplify Alternative Harvest ETFMJ
Market value
11.58M
Weight
9.77%
AUM
118.56M USD
Expense ratio
1.12%
Price / 1D
$26.645—
AdvisorShares Pure Cannabis ETF logoAdvisorShares Pure Cannabis ETFYOLO
Market value
1.66M
Weight
4.57%
AUM
36.39M USD
Expense ratio
0.91%
Price / 1D
$3.025—
Dimensional - International Small Cap ETF logoDimensional - International Small Cap ETFDFIS
Market value
1.4M
Weight
0.02%
AUM
5.91B USD
Expense ratio
0.39%
Price / 1D
$37.46—
Dimensional - International Core Equity 2 ETF logoDimensional - International Core Equity 2 ETFDFIC
Market value
1.26M
Weight
0.01%
AUM
15.43B USD
Expense ratio
0.22%
Price / 1D
$39.315—
Dimensional World ex U.S. Core Equity 2 ETF logoDimensional World ex U.S. Core Equity 2 ETFDFAX
Market value
686.54K
Weight
0.01%
AUM
12.57B USD
Expense ratio
0.28%
Price / 1D
$37.93—
Amplify Seymour Cannabis ETF logoAmplify Seymour Cannabis ETFCNBS
Market value
426.86K
Weight
0.52%
AUM
82.1M USD
Expense ratio
1.09%
Price / 1D
$28.47—
Dimensional - International Core Equity Market ETF logoDimensional - International Core Equity Market ETFDFAI
Market value
51.16K
Weight
0.00%
AUM
18.23B USD
Expense ratio
0.18%
Price / 1D
$43.255—
Dimensional - International Vector Equity ETF logoDimensional - International Vector Equity ETFDXIV
Market value
42.17K
Weight
0.02%
AUM
222.84M USD
Expense ratio
0.53%
Price / 1D
$74.8501—

Continue in GoAI

Research CRON

research.disclaimer